White Paper explores Theramine® as a Safe and Clinically Effective Alternative to Common Pain Medications
Los Angeles, CA, October 6, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine, as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation.
According to Consumer Reports, the overuse of opioid pain medications has reached epidemic proportions in the United States, and poses a significant public health problem. Roughly 45 people a day and more than 16,600 people a year, die from overdoses of these drugs, including methadone, morphine, andoxycodone (OxyContin) and hydrocodone combined with acetaminophen (Lortab and Vicodin). On September 30, 2014, the American Academy of Neurology published their new position regarding opioids, stating that the risks of opioids outweigh the benefits for headache, low back pain and other chronic conditions.
Theramine, a medical food specially formulated to address the increased amino acid requirements of pain syndromes, has been used clinically to manage back pain, migraines, Fibromyalgia and other pain syndromes since 2004 as an adjunct and replacement therapy to opioid, NSAID and anti-epileptic pain medications by physicians throughout the United States. Theramine, has been the subject of two double-blind clinical trials which are published in the American Journal of Therapeutics. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain than both naproxen and ibuprofen and proved to be effective at increasing specific amino acid levels in study subjects.
“The overprescribing of narcotic pain medications and the overuse of NSAIDs is a growing problem that our company and products can help address,” said William Shell M.D., CEO and Chief Science Officer at Targeted Medical Pharma. “Theramine is an effective clinical tool for physicians interested in managing pain and inflammation without the GI or cardiovascular side effects associated with NSAIDs or the addictive potential of narcotics.”
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.
The company also develops a line of dietary supplements designed to support health and wellness. TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.
# # # #